FDA Should Do More To Boost Transparency To Industry, Firms Say
This article was originally published in The Gray Sheet
FDA's plans to improve transparency with industry do not go far enough, device and biotech firms say in recent comments to the agency.
You may also be interested in...
FDA pre-market approval reviews tend to take longer when the medical officer leaves the review team, when clinical trial data issues arise and when companies engage in "excessive" back and forth with FDA during the review process, according to a recent FDA analysis.
Included in a new list of things FDA will do to improve its communications with manufacturers is a vow to respond more quickly to industry questions.
At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.